Programmed death-ligand 1 tumor proportion score in predicting the safety and efficacy of PD-1/PD-L1 antibody-based therapy in patients with advanced non-small cell lung cancer: A retrospective, multicenter, observational study
Yuequan Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Qing Zhou(Chinese Academy of Medical Sciences & Peking Union Medical College), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Chengzhi Zhou(First Affiliated Hospital of Guangzhou Medical University), Yangchun Gu(Peking University), Cuiying Zhang(Tianjin University of Science and Technology), Yongjie Shui(Second Affiliated Hospital of Zhejiang University), Jian Fang(Peking University), Haoran Zhang(Urban Planning & Design Institute of Shenzhen (China)), Jia Liu(Chinese Academy of Medical Sciences & Peking Union Medical College), Dongming Zhang(Heilongjiang Bayi Agricultural University), Jian Zhao(Aarhus University), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Siyuan Yu(Jiangsu University), Anwen Liu(Nanchang University), Cuimin Ding(Hebei Medical University), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Xiaoxing Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Bin Ai(Beijing Hospital), Yan Wang(National Institute of Biological Sciences, Beijing), Qingwei Meng(Harbin Medical University)
Cited by 1
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients
|Clinical Cancer Research|2018|551
Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial
|The Lancet Respiratory Medicine|2020|508
Nuclear actin and myosin I are required for RNA polymerase I transcription
|Nature Cell Biology|2004|406
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
|Journal of Thoracic Oncology|2021|311